Pathology - Research and Practice, Год журнала: 2024, Номер 266, С. 155785 - 155785
Опубликована: Дек. 19, 2024
Язык: Английский
Pathology - Research and Practice, Год журнала: 2024, Номер 266, С. 155785 - 155785
Опубликована: Дек. 19, 2024
Язык: Английский
Sensors and Actuators A Physical, Год журнала: 2024, Номер 376, С. 115625 - 115625
Опубликована: Июнь 24, 2024
The integration of CRISPR technology with microfluidic-based biosensors has greatly expanded its applications in medicine and molecular biology. This combination offers enhanced sensitivity selectivity medical diagnostics. CRISPR-powered microfluidics enables the accurate quantification DNA RNA associated diseases such as cancer, viral infections, bacterial diseases. precise targeting capabilities allow for detection specific genetic sequences, aiding early diagnosis, disease monitoring, treatment assessment. improves specificity by leveraging programmable nature coupling it signal readouts. However, challenges assay optimization, standardization, device fabrication need to be addressed. Additionally, complexity presents potential limitations terms off-target effects unintended modifications. Overall, holds tremendous diagnostics, but further research development are required fully exploit benefits clinical settings.
Язык: Английский
Процитировано
18Biomedicines, Год журнала: 2024, Номер 12(12), С. 2750 - 2750
Опубликована: Ноя. 30, 2024
The field of personalized medicine is undergoing a transformative shift through the integration multi-omics data, which mainly encompasses genomics, transcriptomics, proteomics, and metabolomics. This synergy allows for comprehensive understanding individual health by analyzing genetic, molecular, biochemical profiles. generation data enable more precise tailored therapeutic strategies, improving efficacy treatments reducing adverse effects. However, several challenges hinder full realization medicine. Key hurdles include complexity across different omics layers, need advanced computational tools, high cost generation. Additionally, issues related to privacy, standardization, robust validation in diverse populations remain significant obstacles. Looking ahead, future promises advancements technology methodologies that will address these challenges. Emerging innovations analytics, machine learning, high-throughput sequencing are expected enhance making accessible effective. Collaborative efforts among researchers, clinicians, industry stakeholders crucial overcoming fully harnessing potential individualized healthcare.
Язык: Английский
Процитировано
10Chemistry & Biodiversity, Год журнала: 2024, Номер 21(7)
Опубликована: Май 3, 2024
Recent breakthroughs in the field of carbon nanotubes (CNTs) have opened up unprecedented opportunities for development specialized bioactive CNT-polymers a variety biosensor applications. The incorporation materials, including DNA, aptamers and antibodies, into CNTs to produce composites has attracted considerable attention. In addition, polymers are essential biosensors as they provide biocompatible conditions ideal matrix immobilization proteins. numerous applications compounds combined with excellent chemical physical properties led CNT-polymer composites. This article provides comprehensive overview new approaches encapsulate CNTs. Finally, detection glucose, H
Язык: Английский
Процитировано
4Placenta, Год журнала: 2024, Номер 157, С. 5 - 13
Опубликована: Фев. 23, 2024
Язык: Английский
Процитировано
1ChemMedChem, Год журнала: 2024, Номер unknown
Опубликована: Окт. 17, 2024
Abstract Tetraspanins are key players in various physiological and pathological processes, including malignancy, immune response, fertilization, infectious disease. Affinity ligands targeting the interactions between tetraspanins partner proteins promising for modulating downstream signaling pathways, thus emerging as attractive candidates interfering related biological functions. Due to involvement vesicle biogenesis cargo trafficking, also regarded exosome markers, become molecular targets drug loading delivery. Given rapid development these areas, this minireview focuses on recent advances design engineering of affinity binders toward CD63, CD81, CD9. Their mechanism actions protein at cell interfaces treatment malignant diseases discussed. Strategies constructing exosome‐based delivery platforms reviewed, with emphasis important roles ligands. Finally, challenges future tetraspanin‐targeting therapy exosomal
Язык: Английский
Процитировано
1Pathology - Research and Practice, Год журнала: 2024, Номер 266, С. 155785 - 155785
Опубликована: Дек. 19, 2024
Язык: Английский
Процитировано
1